What is the recommended first‑line treatment strategy for an adult with metastatic renal cell carcinoma, considering performance status, IMDC risk factors, and options for immunotherapy versus VEGF‑targeted therapy, and what are the appropriate second‑line options if the disease progresses?

Treatment of Metastatic Renal Cell Carcinoma

For adults with metastatic clear cell RCC, first-line treatment should be risk-stratified using IMDC criteria, with combination immunotherapy (nivolumab-ipilimumab) or ICI plus VEGFR-TKI (pembrolizumab-axitinib, nivolumab-cabozantinib, or pembrolizumab-lenvatinib) recommended for intermediate- and poor-risk patients, while favorable-risk patients may receive either combination therapy or VEGFR-TKI monotherapy; second-line options after progression include cabozantinib or nivolumab depending on prior therapy. 1

Risk Stratification Using IMDC Criteria

All patients must be stratified into IMDC risk groups before selecting therapy, as this directly determines treatment selection and prognosis 1:

• IMDC criteria include 6 adverse factors: Karnofsky performance status <80%, time from diagnosis to treatment <1 year, hemoglobin below lower limit of normal, corrected calcium above upper limit of normal, absolute neutrophil count above upper limit of normal, and platelets above upper limit of normal 1

• Risk categories:

  • Favorable risk: 0 factors (median OS 35.3 months in second-line setting, 2-year OS 75% in first-line) 1, 2
  • Intermediate risk: 1-2 factors (median OS 16.6-27 months, 2-year OS 53%) 1
  • Poor risk: 3-6 factors (median OS 5.4-8.8 months, 2-year OS 7%) 1

First-Line Systemic Therapy

Intermediate- and Poor-Risk Disease

Combination therapy is mandatory for intermediate- and poor-risk patients 1, 3:

Preferred regimens (all Level I, A evidence):

• Nivolumab plus ipilimumab: OS HR 0.72 vs sunitinib, 18-month OS of 78% (intermediate-risk) and 50% (poor-risk), complete response rate 12% 1

• Pembrolizumab plus axitinib: OS HR 0.73 vs sunitinib, overall response rate 60%, complete response rate 10% 1, 3

• Nivolumab plus cabozantinib: OS HR 0.70 vs sunitinib, PFS HR 0.56, overall response rate 56%, complete response rate 12% 1, 3

• Pembrolizumab plus lenvatinib: OS HR 0.72 vs sunitinib, PFS HR 0.42, overall response rate 69%, complete response rate 17% 1, 3

Special consideration for poor-risk patients with bone metastases: Cabozantinib-nivolumab is the preferred regimen, showing improved PFS (HR 0.34; 95% CI 0.22-0.55) and OS (HR 0.54; 95% CI 0.32-0.92) in the bone metastases subgroup 4

Favorable-Risk Disease

For favorable-risk patients, either combination therapy or VEGFR-TKI monotherapy is acceptable 1:

• VEGFR-TKI monotherapy options: Sunitinib, pazopanib, or tivozanib are appropriate alternatives, as OS data for ICI combinations in favorable-risk disease remain immature and do not show clear superiority 1, 5

• ICI-VEGFR combinations may be preferred if better response rates (60-69% vs 39%) and PFS are prioritized over the uncertain OS benefit 1, 6

• Active surveillance may be appropriate for highly selected favorable-risk patients with low tumor burden, long interval from nephrectomy, limited metastatic sites, and no symptoms 1, 3

Monotherapy Considerations

Single-agent therapy should only be used in exceptional circumstances 1, 3:

• Select patients with coexisting medical problems precluding combination therapy may receive VEGFR-TKI monotherapy (sunitinib, pazopanib, cabozantinib) or single-agent ICI 1, 5

• High-dose IL-2 may be considered but has been largely replaced by newer immunotherapy regimens and should only be administered at experienced high-volume centers 1, 3

Special Clinical Scenarios

Bone Metastases

• Initiate zoledronic acid or denosumab immediately alongside systemic therapy to prevent skeletal-related events 4
• Administer bone-directed radiation therapy for symptomatic lesions 4, 3
• Prefer cabozantinib-containing regimens for patients with bone involvement 4, 3

Brain Metastases

• ICI-based combination therapy is preferred for first-line treatment 3
• Brain-directed local therapy with radiation and/or surgery is recommended 3
• Stereotactic radiosurgery with or without whole-brain radiotherapy should be considered for single unresectable brain metastases in good-prognosis patients 1

Sarcomatoid Features

• ICI-based combination therapy is strongly recommended, as these regimens show particularly high activity in sarcomatoid histology 1, 3

Cytoreductive Nephrectomy

Cytoreductive nephrectomy should be highly selective and not performed routinely 1:

• Appropriate candidates: Patients with one IMDC risk factor (intermediate-risk), majority of tumor burden in the kidney, good performance status, no brain/bone/liver metastases, and surgically resectable primary tumor 1

• Contraindicated in poor-risk patients: IMDC poor-risk patients should receive immediate systemic therapy, as the CARMENA trial showed sunitinib alone had longer median OS (18.4 vs 13.9 months) compared to immediate cytoreductive nephrectomy followed by sunitinib 4, 3

• Delayed cytoreductive nephrectomy may be considered in poor-risk patients with good response to systemic treatment 1

Second-Line Therapy

After First-Line ICI-Based Therapy

VEGFR-TKI therapy is the standard second-line approach after ICI progression 1:

• Cabozantinib is the preferred agent (Level II, B evidence), with response rates of 20-40% in retrospective analyses 1, 5

• Alternative options include axitinib, pazopanib, sunitinib, tivozanib, or lenvatinib-everolimus, all showing similar efficacy in retrospective studies 1

• Further ICI therapy after first-line PD-1-targeted combination is not recommended and potentially harmful 1

After First-Line VEGFR-TKI Therapy

Either nivolumab or cabozantinib is recommended (both Level I, A evidence) 1, 3, 5:

• Nivolumab monotherapy: Superior OS compared to everolimus (25.8 vs 19.7 months, HR 0.73) with improved toxicity profile 3

• Cabozantinib: Level I, A evidence with OS benefit 1, 5

• Lenvatinib plus everolimus is FDA- and EMA-approved (Level II, B evidence) 1

After Two Prior TKIs

• Nivolumab (Level I, A evidence) or cabozantinib is recommended 1

Treatment Duration and Monitoring

• Continue systemic therapy until disease progression or unacceptable toxicity 4
• PD-1 inhibitors in combination regimens are typically stopped after 2 years, though optimal duration beyond 2 years is uncertain 1
• For patients on immunotherapy with limited disease progression, local therapy (radiation, ablation, excision) may be offered while continuing immunotherapy 3
• Follow-up during systemic therapy should include CT scans every 2-4 months 1

Critical Pitfalls to Avoid

• Never use single-agent nivolumab as first-line therapy, even in poor performance status patients, as this represents suboptimal treatment that may compromise survival 3
• Do not perform cytoreductive nephrectomy in IMDC poor-risk patients before systemic therapy 4, 3
• Do not continue or re-challenge with ICI therapy after progression on first-line ICI-based combination therapy 1
• Do not fail to risk-stratify patients before selecting therapy, as IMDC criteria directly determine optimal treatment selection 1, 3, 7
• Do not use high-dose IL-2 outside experienced high-volume centers if this option is considered 1, 3